Weiss Ratings Reiterates "Hold (C+)" Rating for HealthEquity (NASDAQ:HQY)

Key Points

• Weiss Ratings has reaffirmed a "Hold (C+)" rating for HealthEquity (NASDAQ:HQY), indicating a neutral outlook for the stock.
• Several analysts have issued varied ratings and target prices, with KeyCorp reducing its target to $120.00, while JPMorgan raised it to $126.00, creating a consensus rating of "Moderate Buy."
• Insider selling was noted, with executives Michael Henry Fiore and Delano Ladd both divesting shares, representing a decrease in their ownership stakes in the company.

HealthEquity (NASDAQ:HQY - Get Free Report)'s stock had its "hold (c+)" rating reaffirmed by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also issued reports on HQY. KeyCorp reduced their target price on shares of HealthEquity from $125.00 to $120.00 and set an "overweight" rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. upped their target price on shares of HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 3rd. Barrington Research reiterated an "outperform" rating and set a $125.00 target price on shares of HealthEquity in a research report on Friday, August 29th. Royal Bank Of Canada upped their target price on shares of HealthEquity from $109.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 3rd. Finally, Jefferies Financial Group increased their price objective on shares of HealthEquity from $130.00 to $134.00 and gave the company a "buy" rating in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $121.31.

HealthEquity Price Performance

Shares of HealthEquity stock opened at $92.09 on Wednesday. HealthEquity has a 1-year low of $74.07 and a 1-year high of $116.65. The firm's 50-day moving average price is $91.71 and its two-hundred day moving average price is $93.82. The stock has a market capitalization of $7.93 billion, a price-to-earnings ratio of 55.81, a P/E/G ratio of 1.27 and a beta of 0.47. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.47.

Insider Activity at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 1,781 shares of the company's stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the completion of the sale, the executive vice president owned 49,795 shares of the company's stock, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Delano Ladd sold 6,000 shares of the company's stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the completion of the sale, the executive vice president directly owned 79,456 shares of the company's stock, valued at $7,477,604.16. The trade was a 7.02% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On HealthEquity

Large investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC increased its position in shares of HealthEquity by 24.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock worth $564,000 after acquiring an additional 1,265 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of HealthEquity by 7,983.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,655 shares of the company's stock worth $2,179,000 after acquiring an additional 24,350 shares in the last quarter. GAMMA Investing LLC increased its position in shares of HealthEquity by 25.9% during the first quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock worth $139,000 after acquiring an additional 323 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of HealthEquity by 995.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company's stock worth $56,500,000 after acquiring an additional 580,988 shares in the last quarter. Finally, WCM Investment Management LLC bought a new stake in shares of HealthEquity during the first quarter worth $20,230,000. Institutional investors own 99.55% of the company's stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.